Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study
…, G Piaggio, G Ciliberto, A Morrone, F Locatelli, V Sinno… - medRxiv, 2022 - medrxiv.org
Background Patients with solid or hematological tumors, neurological and immune-inflammatory
disorders represent potentially fragile subjects with increased risk to experience severe …
disorders represent potentially fragile subjects with increased risk to experience severe …
[HTML][HTML] Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional …
…, F Baldanti, F Locatelli, N Silvestris, V Sinno… - Frontiers in …, 2023 - frontiersin.org
Introduction Immunocompromised patients have been shown to have an impaired immune
response to COVID-19 vaccines. Methods Here we compared the B-cell, T-cell and …
response to COVID-19 vaccines. Methods Here we compared the B-cell, T-cell and …
Humoral and T-cell immune response after 3 doses of messenger RNA severe acute respiratory syndrome coronavirus 2 vaccines in fragile patients: the Italian …
…, A Morrone, F Locatelli, V Sinno… - Clinical Infectious …, 2023 - academic.oup.com
Background Patients with solid or hematological tumors or neurological and immune-inflammatory
disorders are potentially fragile subjects at increased risk of experiencing severe …
disorders are potentially fragile subjects at increased risk of experiencing severe …
[HTML][HTML] Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders
…, M Vitali, N Zilembo, E Haspinger, V Sinno… - Cancer treatment …, 2014 - Elsevier
The treatment of advanced disease (stage IIIb and IV) of non-small cell lung cancer (NSCLC)
is based on systemic treatment with platinum-based chemotherapy or biological …
is based on systemic treatment with platinum-based chemotherapy or biological …
Lessons learned from COVID-19 for clinical research operations in Italy: what have we learned and what can we apply in the future?
…, S Stabile, S Testoni, P Trogu, V Sinno… - Tumori …, 2021 - journals.sagepub.com
The coronavirus disease 2019 (COVID-19) pandemic has stressed the importance of health
research as never before. In the specific domain of clinical research, the effort to rapidly find …
research as never before. In the specific domain of clinical research, the effort to rapidly find …
[HTML][HTML] mRNA-COVID19 vaccination can be considered safe and tolerable for frail patients
…, G Ciliberto, F Baldanti, A Morrone, V Sinno… - Frontiers in …, 2022 - frontiersin.org
Background Frail patients are considered at relevant risk of complications due to coronavirus
disease 2019 (COVID-19) infection and, for this reason, are prioritized candidates for …
disease 2019 (COVID-19) infection and, for this reason, are prioritized candidates for …
[HTML][HTML] Phase I study of rucaparib in combination with bevacizumab in ovarian cancer patients: maximum tolerated dose and pharmacokinetic profile
…, M Zucchetti, F Raspagliesi, C Sonetto, V Sinno… - Targeted Oncology, 2021 - Springer
Background Targeted agents, such as antiangiogenic drugs (eg, bevacizumab) and poly(ADP-ribose)
polymerase inhibitors (eg, rucaparib), have been shown to improve outcomes in …
polymerase inhibitors (eg, rucaparib), have been shown to improve outcomes in …
[HTML][HTML] SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region
CM Ciniselli, A Micali, L De Cecco, P Notti, V Sinno… - Cancers, 2021 - mdpi.com
Simple Summary Since the beginning of the COVID-19 outbreak, Cancer Centers adopted
specific procedures to protect patients as well as to monitor the possible spread of SARS-CoV…
specific procedures to protect patients as well as to monitor the possible spread of SARS-CoV…
mRNA-COVID19 vaccination can be considered safe and tolerable for frail patients
…, G Ciliberto, F Baldanti, A Morrone, V Sinno… - medRxiv, 2022 - medrxiv.org
Background Frail patients are considered at relevant risk of complications due to COVID-19
infection and, for this reason, are prioritized candidates for vaccination. As these patients …
infection and, for this reason, are prioritized candidates for vaccination. As these patients …
[HTML][HTML] Features and Prognostic Factors of Large Node-Negative Non–Small-Cell Lung Cancers Shifted to Stage II
F Toffalorio, D Radice, L Spaggiari, V Sinno… - Journal of Thoracic …, 2012 - Elsevier
Background: During the period that randomized clinical trials were establishing the role of
adjuvant therapy in tumors larger than 5 cm without lymph-node invasion, which shifted from …
adjuvant therapy in tumors larger than 5 cm without lymph-node invasion, which shifted from …